Appeals Court Upholds Penalty for Lilly Medicaid Price Reporting

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Appeals Court Upholds False Claims Penalty of Over $183M for Lilly’s Medicaid Drug Price Reporting

Dennis Tosh

September 17, 2025 at 08:28 PM EST

A federal appeals court has upheld a False Claims Act penalty against Eli Lilly & Co. totaling more than $183 million stemming from the company’s Medicaid price reporting practices, concluding that the district court jury that considered the whistleblower case “reasonably found Lilly knowingly hid the truth” (United States ex rel. Streck v. Eli Lilly & Co., Nos. 23-213... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Appeals Court Upholds False Claims Penalty of Over $183M for Lilly’s Medicaid Drug Price Reporting

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT